Literature DB >> 15548798

Variations in the morphology of retinopathy of prematurity in extremely low birthweight infants.

W E Schulenburg1, G Tsanaktsidis.   

Abstract

AIMS: To investigate the clinical observations that arteriovenous shunts typical of threshold retinopathy of prematurity (ROP) are morphologically different in extremely low birthweight infants weighing less than 1000 g.
METHODS: An observational case series of six extremely low birthweight infants displaying specific features of threshold retinopathy of prematurity enrolled between 1998 and 2001 at one centre. The variant morphology was documented with colour photography and fundus fluorescein angiography before laser therapy.
RESULTS: Stage 3 threshold ROP in extremely premature infants may be characterised by a different morphology not demonstrating classic shunt formation. A poorly developed capillary bed is present in already vascularised retina in these cases.
CONCLUSIONS: This case series of extremely low birthweight infants display variations in the typical morphological appearance of threshold ROP. In these cases, established plus disease may be present in the absence of arteriovenous shunting. Delaying treatment until a classic stage 3 ridge with extraretinal neovascularisation develops may be detrimental to controlling the disease process. The authors propose that the criteria for threshold disease requiring treatment do not accurately apply in this extremely low birthweight group as defined by the CRYO-ROP study and that treatment should be instituted before the typical threshold features arise. Plus disease remains the most reliable sign indicating the need for treatment.

Entities:  

Mesh:

Year:  2004        PMID: 15548798      PMCID: PMC1772447          DOI: 10.1136/bjo.2004.044669

Source DB:  PubMed          Journal:  Br J Ophthalmol        ISSN: 0007-1161            Impact factor:   4.638


  16 in total

1.  Neonatal outcome of infants born at 500 to 800 grams from 1990 through 1998 in a tertiary care center.

Authors:  Rita G Harper; Khalil U Rehman; Concepcion Sia; Sharon Buckwald; Regina Spinazzola; Jerrold Schlessel; Judith Mestrandrea; Mary Rodgers; Raul A Wapnir
Journal:  J Perinatol       Date:  2002 Oct-Nov       Impact factor: 2.521

2.  Improved outcomes for very low birthweight infants: evidence from New Zealand national population based data.

Authors:  B A Darlow; A E Cust; D A Donoghue
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  2003-01       Impact factor: 5.747

3.  Multicenter trial of cryotherapy for retinopathy of prematurity. One-year outcome--structure and function. Cryotherapy for Retinopathy of Prematurity Cooperative Group.

Authors: 
Journal:  Arch Ophthalmol       Date:  1990-10

4.  An international classification of retinopathy of prematurity. The Committee for the Classification of Retinopathy of Prematurity.

Authors: 
Journal:  Arch Ophthalmol       Date:  1984-08

5.  A comparison of laser photocoagulation with cryotherapy for threshold retinopathy of prematurity at 10 years: part 1. Visual function and structural outcome.

Authors:  Eugene Y J Ng; Brian P Connolly; J Arch McNamara; Carl D Regillo; James F Vander; William Tasman
Journal:  Ophthalmology       Date:  2002-05       Impact factor: 12.079

6.  A comparison of laser photocoagulation with cryotherapy for threshold retinopathy of prematurity at 10 years: part 2. Refractive outcome.

Authors:  Brian P Connolly; Eugene Y J Ng; J Arch McNamara; Carl D Regillo; James F Vander; William Tasman
Journal:  Ophthalmology       Date:  2002-05       Impact factor: 12.079

7.  Multicenter Trial of Cryotherapy for Retinopathy of Prematurity: ophthalmological outcomes at 10 years.

Authors: 
Journal:  Arch Ophthalmol       Date:  2001-08

8.  Revised indications for the treatment of retinopathy of prematurity: results of the early treatment for retinopathy of prematurity randomized trial.

Authors: 
Journal:  Arch Ophthalmol       Date:  2003-12

9.  Diode laser treatment of pre-threshold and threshold retinopathy of prematurity.

Authors:  Graham A Lee; David J Hilford; Glen A Gole
Journal:  Clin Exp Ophthalmol       Date:  2004-04       Impact factor: 4.207

10.  US birth weight/gestational age-specific neonatal mortality: 1995-1997 rates for whites, hispanics, and blacks.

Authors:  Greg R Alexander; Michael Kogan; Deren Bader; Wally Carlo; Marilee Allen; Joanne Mor
Journal:  Pediatrics       Date:  2003-01       Impact factor: 7.124

View more
  6 in total

1.  Case of aggressive posterior retinopathy of prematurity with atypical neovascular growth.

Authors:  Miina Hiraoka; Sachiko Nishina; Atsuko Nakagawa; Kentaro Matsuoka; Noriyuki Azuma
Journal:  Jpn J Ophthalmol       Date:  2008-11-11       Impact factor: 2.447

2.  Wnt signaling mediates pathological vascular growth in proliferative retinopathy.

Authors:  Jing Chen; Andreas Stahl; Nathan M Krah; Molly R Seaward; Roberta J Dennison; Przemyslaw Sapieha; Jing Hua; Colman J Hatton; Aimee M Juan; Christopher M Aderman; Keirnan L Willett; Karen I Guerin; Akiko Mammoto; Matthew Campbell; Lois E H Smith
Journal:  Circulation       Date:  2011-10-03       Impact factor: 29.690

3.  Hyperoxia inhibits several critical aspects of vascular development.

Authors:  Koichi Uno; Carol A Merges; Rhonda Grebe; Gerard A Lutty; Tarl W Prow
Journal:  Dev Dyn       Date:  2007-04       Impact factor: 3.780

4.  Capillary-free vascularized retina in patients with aggressive posterior retinopathy of prematurity and late retinal capillary formation.

Authors:  Seong Joon Ahn; Jeong Hun Kim; Seong-Joon Kim; Young Suk Yu
Journal:  Korean J Ophthalmol       Date:  2013-03-07

Review 5.  Targeting WNT Signaling for Multifaceted Glioblastoma Therapy.

Authors:  Matthew McCord; Yoh-Suke Mukouyama; Mark R Gilbert; Sadhana Jackson
Journal:  Front Cell Neurosci       Date:  2017-10-13       Impact factor: 5.505

6.  Featureless retina in diabetic retinopathy: Clinical and fluorescein angiographic profile.

Authors:  Dhananjay Shukla; Anuradha Dhawan; Jay Kalliath
Journal:  Indian J Ophthalmol       Date:  2021-11       Impact factor: 1.848

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.